GlassScriptPhysician profile
Trevor T Muirhead
NPI 1386819241
$5,950.89
in general payments reported to CMS, 2019-2025
31 companies · $837 in 2025
The $837 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $913 · 2020: $624 · 2021: $824 · 2022: $807 · 2023: $1,050 · 2024: $897 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,783.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,783.56 | 2019-2025 | |
| Abbvie INC. | $1,466.54 | 2020-2025 | |
| Janssen Biotech, INC. | $582.76 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Genzyme Corporation | $316.99 | 2020-2024 | |
| Sun Pharmaceutical Industries INC. | $221.49 | 2019-2025 | |
| Pfizer INC. | $202.99 | 2019-2023 | |
| Amgen INC. | $193.73 | 2019-2025 | Otezla |
| Leo Pharma INC. | $183.00 | 2020-2023 | Adbry |
| Lilly USA, LLC | $110.57 | 2019-2024 | Taltz, Olumiant |
| Incyte Corporation | $97.16 | 2021-2025 | Opzelura |
| Ucb, INC. | $94.69 | 2019-2023 | Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $62.81 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $62.40 | 2020-2024 | Dupixent |
| Dermavant Sciences, INC. | $56.94 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $53.93 | 2019-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $49.48 | 2019-2022 | |
| Krystal Biotech INC | $48.47 | 2023 | Vyjuvek |
| E.R. Squibb & Sons, L.L.C. | $48.25 | 2022-2024 | Sotyktu |
| Nuvasive, INC. | $47.69 | 2019 | |
| Strata Skin Sciences, INC. | $44.34 | 2021-2024 | Xtrac |
| Dusa Pharmaceuticals, INC. | $34.60 | 2019 | |
| Kyowa Kirin, INC. | $32.42 | 2023 | Poteligeo |
| Vyne Pharmaceuticals INC. | $28.33 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.53 | 2023 | Spevigo |
| Celgene Corporation | $21.09 | 2019 | |
| Merck Sharp & Dohme LLC | $17.44 | 2019 | |
| Dermira, INC. | $17.02 | 2020 | |
| Epi Health, LLC | $13.92 | 2022 | |
| Mylan Pharmaceuticals INC. | $13.19 | 2019 | |
| Prugen, INC. Pharmaceuticals | $12.79 | 2019 | |
| Journey Medical Corporation | $7.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trevor Muirhead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.